Mustafa Javaid

Mustafa Javaid

Auto-generated profile, based on publicly available information

Mustafa Javaid

Oxford University Hospitals, Oxford, UK

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
MJMustafa Javaid
Mustafa Javaid
KKKadhim Kadhim
Kadhim Kadhim
BBBilal Bawamia
Bilal Bawamia
TCTimothy Cartlidge
Timothy Cartlidge
MFMohamed Farag
Mohamed Farag
Mohammad AlkhalilMohammad Alkhalil
Mohammad Alkhalil
Background: There is a potential concern about increased bleeding risk in patients receiving omega‐3 polyunsaturated fatty acids (PUFAs). The aims of this study‐level meta‐analysis were to determine the risk of bleeding and to assess whether this relationship is linked to the received dose of omega‐3 PUFAs or the background use of antiplatelet treatment. Methods and Results: Electronic databases were searched through May 2023 to identify randomized clinical trials of patients receiving omega‐3 PUFAs. Overall bleeding events, including fatal and central nervous system events, were identified and compared with those of a control group. A total of 120 643 patients from 11 randomized clinical trials were included. There was no difference in the pooled meta‐analytic events of bleeding among patients receiving omega‐3 PUFAs and those in the control group (rate ratio [RR], 1.09 [95% CI, 0.91–1.31]; P =0.34). Likewise, the incidence of hemorrhagic stroke, intracranial bleeding, and gastrointestinal bleeding were similar. A prespecified analysis was performed in patients receiving high‐dose purified eicosapentaenoic acid (EPA), which demonstrated a 50% increase in the relative risk of bleeding but only a modest increase in the absolute risk of bleeding (0.6%) when compared with placebo. Bleeding risk was associated with the dose of EPA (risk difference, 0.24 [95% CI, 0.05–0.43]; P =0.02) but not the background use of antiplatelet therapy (risk difference, −0.01 [95% CI, −0.02 to 0]; P =0.056). Conclusions: Omega‐3 PUFAs were not associated with increased bleeding risk. Patients receiving high‐dose purified EPA may incur additional bleeding risk, although its clinical significance is very modest.

7 July 2026 in Open Medicine
Verified
Journal Article
Open access
KRKhalid Rashid
Khalid Rashid
AHAhmedyar Hasan
Ahmedyar Hasan
MJMustafa Javaid
Mustafa Javaid
FAFarrukh Ansar
Farrukh Ansar
YKYahya Khan
Yahya Khan
MWMuhammad Aamir Waheed
Muhammad Aamir Waheed
To compare the mortality and clinical outcomes of transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR) in patients with low- or intermediate-risk symptomatic severe aortic stenosis through an updated systematic review and meta-analysis of randomized controlled trials. This systematic review was performed using PubMed, Medline, Embase, and Cochrane databases for RCTS between 2017 and 2024 which evaluated mortality outcomes in patients with low to intermediate risk AS who received TAVI vs. SAVR. Relative risks (RRs) with 95 % confidence intervals (CIs) were pooled using random effects models. TAVI showed a numerically lower but statistically insignificant mortality risk compared to SAVR (RR: 0.88, 95 % CI: 0.62–1.25, p=0.49). TAVI was associated with a higher risk of PPM insertion (RR: 2.19, 95 % CI: 1.55–3.16, p<0.001, i2: 80 %), aortic valve re-intervention (RR: 2.51, 95 % CI: 1.40–4.51, p<0.001; I2=0 %), new-onset bundle branch block (RR: 2.10, 95 % CI: 1.21–3.67, p<0.01; I2=84 %), and vascular site complications (RR: 4.77, 95 % CI: 2.11–10.81, p<0.001; I2=62 %). Atrial fibrillation incidence was lower with TAVI (RR: 0.29, 95 % CI: 0.23–0.38, p<0.001; I2=73). There was no significant difference in the rates of post-procedural myocardial infarction, stroke and endocarditis between TAVI and SAVR. TAVI has mortality outcomes comparable to SAVR in low to intermediate risk patients. TAVI offers advantages in atrial fibrillation reduction, but is associated with increased risk of PPM insertion, vascular complications, new-onset bundle branch block, aortic valve re-intervention. Individualized treatment decisions remain important for optimizing outcomes in low to intermediate risk patients. CRD42024547882.